Condition: Erythroleukoplakia · Leukoplakia · Verrucous Oral Leukoplakia · Sponsor: Jonsson Comprehensive Cancer Center
This phase II pilot trial studies how well pembrolizumab works in treating leukoplakia. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
This description comes directly from the study's public registry record.
Thu P Ly · 310-794-2464 · tply@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Not Yet Recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03603223